Inhibiting the activation of NF-κB signals in microglia and neurons observably mitigate neuroinflammation in brain disease, manifested by down-regulation of pro-inflammatory mediators, such as IL-6, IL-18, iNOS and COX-2, and the loss of neurons (37–39). Here, IL18 is linked to brain disorder.